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ABSTRACT 
 
   Background: Disease specific autoantibodies have been detected in the sera of 
patients with atherosclerosis-related diseases, such as cerebral infarction, 
cardiovascular disease. In the present study, we aimed to identify novel autoantibodies 
responsible for transient ischemic attack (TIA), a prodromal condition for cerebral 
infarction. 
   Methods: To identify candidate antigens, we screened a human aortic endothelial 
cell cDNA library using sera from 20 patients with TIA. Serum antibody levels were 
measured using amplified luminescent proximity homogeneous assay-linked 
immunosorbent assay (AlphaLISA) in 2 independent patient/healthy donor (HD) 
cohorts (n = 192 and n = 906 in the second screening and validation cohort, 
respectively). 
   Results: First screening identified 3 candidate antigens. Of these, programmed cell 
death 11 (PDCD11) was determined to be associated with stroke (p < 0.0001), as 
evidenced from the second screening using AlphaLISA. The validation cohort revealed 
significantly higher antibody levels against PDCD11 (PDCD11-Ab levels) in patients 
with TIA than in HDs. Multivariate logistic regression analysis indicated that the 
predictive value of PDCD11-Ab levels for TIA [Odds ratio (OR): 2.44, 95% confidence 
interval (CI): 1.33–4.57, p = 0.0039] was not inferior to other known risk factors for 
ischemic stroke, including age (OR: 4.97, 95% CI: 2.67–9.48, p < 0.0001); hypertension 
(OR: 3.21, 95% CI: 1.76–5.86, p = 0.0001); and diabetes (OR: 4.31, 95% CI: 1.74–11.2, p 
= 0.0015). 
   Conclusion: Serum PDCD11-Ab level may serve as a potential biomarker for TIA. 
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INTRODUCTION 
 
   Ischemic stroke is one of the major causes of mortality and morbidity worldwide, and one 
of the primary pathological processes responsible for stroke is atherosclerosis [1–3]. 
Atherosclerosis shares characteristics of chronic inflammatory disease, and various immune 
cells have been reported to play roles in atherogenesis [4–8]. Proposed antigenic proteins 
related to atherogenesis that may be recognized by the immune system are oxidized low 
density lipoprotein (oxLDL), phosphorylcholine, heat shock proteins (Hsps), Apolipoprotein 
A1, and phospholipids [9]. 
   Serological identification of antigens by recombinant cDNA expression cloning (SEREX), 
a combination of molecular cloning using phage expression libraries with serological typing, 
is an established method for identifying antigenic proteins [10, 11]. SEREX has been used to 
identify more than 1000 novel cancer antigens and is considered one of the most effective 
methods for identifying antigenic targets on a genomic scale [12–14]. Although this method 
was originally developed to screen cancer-associated antigens, it has been applied for 
vascular disorders such as transplant-associated coronary disease [15], Kawasaki disease [16], 
and moyamoya disease [17]. Previously, we have conducted SEREX screening for 
atherosclerotic diseases such as carotid artery stenosis [18] and cerebral infarction [19, 20] 
and identified RPA2, TUBB2C, ATP2B4, and BMP-1 as the associated antigens. 
   Recent clinical studies have focused on early intervention benefits in patients with 
transient ischemic attack (TIA) to prevent the subsequent development of cerebral infarction 
[21]. However, the diagnosis of TIA is sometimes difficult because of the lack of objective 
evidences detected by various medical examinations such as magnetic resonance imaging 
(MRI), echo cardiogram, and Holter electrocardiogram. In this context, the diagnosis of TIA 
by convenient blood analysis can be useful. In this study, we aimed to identify autoantibodies 
responsible for TIA by screening a human aortic endothelial cell cDNA library using the sera 
of patients with TIA. 
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MATERIALS AND METHODS 
 
Ethical approval 
   This study was approved by the Local Ethical Review Board of the Graduate School of 
Medicine, Chiba University, as well as those of co-operating hospitals, and it was performed 
in accordance with the principles of the Declaration of Helsinki. Recombinant DNA studies 
were performed with official permission from the Graduate School of Medicine, Chiba 
University, and conducted in conformity with the rules of the Japanese government. Written 
informed consents were obtained from all participants. 
 
Sera from patients and healthy donors 
   Patients who suffered ischemic stroke and were admitted to 3 participant hospitals within 
2 weeks from stroke onset were included in the study. Healthy donors (HDs) included 
individuals without a history of ischemic stroke who underwent medical checkups including 
cerebral MRI. Patients with autoimmune diseases were excluded from this study. The study 
population consisted of 3 independent cohorts: first screening, second screening, and 
validation cohort. 
   Twenty Japanese adults with TIA were selected for the first screening cohort, and the 
second screening involved 96 patients with acute cerebral infarction (aCI) and 96 HDs. In 
order to evaluate relations between antibody levels and other clinical parameters associated 
with ischemic stroke, 621 patients and 285 HDs were allocated to the validation cohort. Of 
621 patients in the validation cohort, 65, 464, and 92 suffered chronic cerebral infarction 
(cCI), aCI, and TIA. Clinical characteristics of patients and HDs are shown in Table 1. 
Furthermore, to validate the relations of antibody levels with acute myocardial infarction 
(AMI) and diabetes mellitus (DM), each 128 age-matched patients and HDs were selected. 
   Sera of patients with TIA, cCI, and aCI were obtained from Chiba Prefectural Sawara 
Hospital, Chiba Rosai Hospital, and Chiba Aoba Municipal Hospital. Sera of patients with 
AMI and DM were obtained from Kyoto University Hospital and Chiba University Hospital, 
respectively. Sera of HDs were obtained from Chiba Prefectural Sawara Hospital, Higashi 
Funabashi Hospital, and Port Square Kashiwado Clinic. After collection, samples were 
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centrifuged at 3,000 ×g for 10 min at room temperature, and the supernatants were stored at  
–80°C until use. Repeated thawing and freezing of samples were avoided. 
 
Clinical data 
   Data regarding the risk factors for atherosclerosis, including age, gender, hypertension, 
diabetes, hyperlipidemia, cardiovascular disease (CVD), obesity, and smoking were collected 
from patients’ clinical records. Hypertension was defined as a history of systolic blood 
pressure > 140 mmHg, diastolic blood pressure > 90 mmHg, or use of antihypertensive 
agents. Diabetes was defined as having a history of diabetes diagnosed and/or treated with 
medication and/or fasting blood glucose ≥ 126 mg/dl. Hyperlipidemia was defined as a 
history of total cholesterol > 220 mg/dL, triglycerides > 150 mg/dL, or use of lipid-lowering 
agents. CVD was defined the presence of myocardial infarction or angina pectoris histories. 
Patients were considered smokers if they smoked during the study period or had a history of 
smoking, and obesity was defined as body mass index (BMI) ≥ 25. The definition of TIA was 
determined by the presence of a transient episode of neurological dysfunction caused by focal 
brain, spinal cord, or retinal ischemia, without acute infarction [22]. 
 
Screening by expression cloning 
   Immunoscreening was performed using a modified version of previously published 
methods [18–20, 23, 24]. We used a commercially available human aortic endothelial cell 
cDNA library (Uni-ZAP XR Premade Library, Stratagene, La Jolla, CA) to screen for clones 
that were immunoreactive against sera of patients with TIA. Escherichia coli (E. coli) 
XL1-Blue MRFʹ was infected with Uni-ZAP XR phage, and the expression of resident cDNA 
clones was induced after blotting inflectional bacteria onto nitrocellulose membranes 
(NitroBind, Osmonics, Minnetonka, MN), which were pretreated with 10 mM 
isopropyl-β-D-thiogalactoside (IPTG) (Wako Pure Cemicals, Osaka, Japan) for 30 min. 
Membranes with bacterial proteins were washed 3 times with TBS-T [20 mM Tris-HCl (pH 
7.5), 0.15 M NaCl and 0.05% Tween-20], and nonspecific binding was blocked by incubating 
membranes with 1% protease-free bovine serum albumin (Nacalai Tesque, Inc., Kyoto, 
Japan) in TBS-T for 1 h. Membranes were then incubated overnight with 1:2000 diluted sera 
7 
 
of patients. After 3 washes with TBS-T, membranes were incubated for 1 h with 1:5000 
diluted alkaline phosphatase-conjugated goat anti-human IgG (Jackson ImmunReseach 
Laboratories, West Grove, PA). Positive reactions were visualized by incubating membranes 
in a color development solution [100 mM Tris-HCl (pH 9.5), 100 mM NaCl, 5 mM MgCl2] 
containing 0.15 mg/ml of 5-bromo-4-chloro-3-indolylphospate (Wako Pure Chemicals) and 
0.3 mg/ml of nitro blue tetrazolium (Wako Pure Chemicals). Positive clones were re-cloned 
for 2 additional times in order to obtain monoclonality as previously described [18–20, 23, 
24]. 
 
Sequence analysis of identified antigens 
   Monoclonalized phage cDNA clones were converted to pBluescript phagemids by in vivo 
excision using ExAssist helper phage (Stratagene). Plasmid DNA was obtained from the E. 
coli SOLR strain after transformation with the phagemid. Inserted cDNAs were sequenced 
and analyzed for homology with a public database provided by the National Center for 
Biotechnology Information (NCBI) (http://www.ncbi.nlm.nih.gov/Blast.cgi/). 
 
Construction of expression vectors 
   The expression plasmids of glutathione-S-transferase (GST)-fused proteins were 
constructed by recombining the cDNA sequences into pGEX-4T vectors (GE Healthcare Life 
Sciences, Pittsburgh, PA), as previously described [18–20, 24]. The pBluescript plasmids 
containing cDNA inserts were digested with EcoRI and XhoI and separated via agarose gel 
electrophoresis. Inserted cDNA fragments were isolated using GenElute
TM
 Minus EtBr Spin 
Columns (Merck, Darmstadt, Germany) and were ligated in frame to pGEX-4T using a 
Ligation-Convenience Kit (Nippon Gene, Toyama, Japan). Ligation mixtures were used to 
transform ECOS
TM
-competent E. coli BL-21 (Nippon Gene). 
 
Purification of recombinant candidate protein 
   Transformed E. coli BL-21 cells containing pGEX-4T clones were cultured in 200 ml of 
Luria broth and treated with 0.1 mM IPTG for 3 h. IPTG-treated cells were then harvested, 
washed with phosphate-buffered saline (PBS), and lysed by sonication in BugBuster Master 
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Mix (Merck). Subsequently, cell lysates were centrifuged at 13,000 × g for 10 min at 4°C. 
Precipitates containing recombinant proteins were dissolved in 8 M urea in TED buffer [50 
mM Tris-HCl (pH 8.0), 1 mM EDTA, and 1 mM dithiothreitol], followed by stepwise 
dialysis using 4 M and 2 M urea in TED buffer for 1 h each. Samples were further dialyzed 
using TED buffer for more than 12 h and were centrifuged at 10,000 × g for 30 min at 4°C. 
Recombinant proteins recovered in the supernatant were purified using glutathione-Sepharose 
column chromatography (GE Healthcare Life Sciences) according to the manufacturer’s 
instructions, and the purified proteins were concentrated using Amicon Ultra-15 Centrifugal 
Filter Device (Merck) [25]. 
 
Western blotting 
   GST and GST-PDCD11 proteins (0.4 μg) were electrophoresed on SDS-polyacrylamide 
gels followed by western blotting using anti-GST antibody (Rockland, Gilbertsville, PA) or 
sera from patients with aCI or TIA. After incubation with horseradish peroxidase-conjugated 
secondary antibody, immunoreactivity was detected with Immobilon (Merck), as previously 
described [18, 26, 27]. 
 
AlphaLISA 
   Amplified luminescent proximity homogeneous assay-linked immunosorbent assay 
(AlphaLISA) was performed using 384-well microtiter plates (white opaque OptiPlate
TM
, 
Perkin Elmer, Waltham, MA) containing 2.5 μl of 1:100 diluted sera and 2.5 μl of GST or 
GST-fusion proteins (10 μg/ml) in AlphaLISA buffer [25 mM HEPES (pH 7.4), 0.1% casein, 
0.5% Triton X-100, 1 mg/ml dextran-500, and 0.05% Proclin-300]. The reaction mixture was 
incubated at room temperature for 6–8 h. Next, anti-human IgG-conjugated acceptor beads 
(2.5 μl of 40 μg/ml) and glutathione-conjugated donor beads (2.5 μl of 40 μg/ml) were added 
and incubated further for 7 days at room temperature in the dark. The chemical emission was 
examind using EnSpire Alpha microplate reader (Perkin Elmer). Specific reactions were 
calculated by subtracting Alpha values of GST control from the values of GST-fusion 
proteins. 
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Immnohistochemistry 
   Tissue samples were obtained from surgically resected brain of a patient with cerebral 
infarction. The samples were fixed with formalin and embedded in paraffin. The samples 
were pretreated by heating them in a heating citrate buffer at 98°C for 40 min. The first 
antibodies used were the monoclonal anti-human PDCD11 antibody (Atras Antibodies, 
Stockholm, Sweden) at a diluteion of 1:100 and incubated overnight at 4°C. The specimens 
were incubated with biotin-labeled rabbit anti-mouse/rabbit-IgG secondary antibody and, 
next, with streptavidin-labeled peroxidase. Sections were counter-stained with hematoxylin 
after the DAB reaction as described in the literature [12]. 
 
Statistical analyses 
   For continuous variables, Mann–Whitney U test or Kruskal–Wallis test were performed 
as appropriate. For categorical variables, chi-square test was performed. Univariate and 
multivariate logistic regression analyses were performed to identify the set of variables that 
could classify participants according to the presence of a history of ischemic stroke. The 
cutoff value of PDCD11-Ab levels for predicting stroke was determined to maximize the sum 
of sensitivity and specificity by receiver operating characteristic (ROC) curve analysis. All 
comparisons were planned and the tests were two-tailed. A p value of less than 0.05 was 
considered statistically significant. Univariate and multivariate logistic regression analyses 
and ROC curve analyses were performed using JMP Pro 13.0.0 software (SAS Institute Inc., 
NC), and other analyses were done using GraphPad Prism 5 (GraphPad Software, La Jolla, 
CA). 
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RESULTS 
 
First screening by expression cloning 
   We screened 2 × 10
6
 cDNA clones using sera of 20 patients with TIA and isolated 36 
reacting clones (Figure 1A). DNA sequence analysis and a search for homologous sequences 
in an NCBI-accessible database indicated that these isolated clones comprised 18 
independent genes. GST-fusion recombinant proteins were successfully produced using 
pGEX-4T vectors in 3 of 18 antigens (Table 2), which included programmed cell death 11 
(PDCD11), catenin alpha 1 (CTNNA1), and ARP3 actin-related protein 3 homolog B 
(ACTR3B). The region of PDCD11 between amino acids 1583 and 1831 was obtained as a 
pBluescript II clone and recombined into pGEX 4T-3 expression vector. Similarly, the cloned 
regions of CTNNA1 and ACTR3B, which were amino acids 313–560 and 94–316, 
respectively, were recombined into pGEX 4T-3 and 4T-1 vectors, respectively. 
 
Secondary screening by AlphaLISA for antibodies against candidate antigens 
   In order to determine whether the 3 antigen candidates were related to ischemic stroke, 
we examined the antibody levels in patients with aCI and HDs in the second screening cohort. 
Serum antibody levels against PDCD11 (PDCD11-Ab levels) were significantly higher in 
patients with aCI than in HDs (p < 0.0001) (Figure 2A). Mean ± SD values of patients and 
HDs were 8843 ± 5217 and 6398 ± 3896, respectively. Antibody levels against CTNNA1 and 
ACTR3B were much lower as compared with those against PDCD11. A significant difference 
in CTNNA1 antibody levels was observed between HDs and patients, whereas no difference 
was noted in ACTR3B antibody levels (Figures 2B and C). 
 
Western blots of purified antigens 
   We confirmed the presence of PDCD11-Ab in patients’ sera by western blot analysis. 
GST-PDCD11 as well as GST proteins were recognized by the anti-GST antibody as 55-kDa 
and 28-kDa proteins, respectively (Figures 1B and C). The molecular weight of the largest 
product was similar to that predicted by sequencing analysis. Moreover, GST-PDCD11 
reacted with serum antibodies of patients with aCI and TIA, but not with HD (Figures 1D–F). 
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Validation of elevated PDCD11-Ab levels in stroke patients 
   To validate the elevated levels of PDCD11-Abs in stroke patients, we further examined 
PDCD11-Ab levels in the independent validation cohort (n = 906). AlphaLISA revealed 
significantly higher PDCD11-Ab levels in patients with cCI (p < 0.0001), aCI (p < 0.0001), 
or TIA (p < 0.0001) as compared with HDs (Figure 2D). Mean ± SD values of patients with 
cCI, aCI, or TIA and HDs were 21230 ± 10413, 20138 ± 9617, 20126 ± 10491, and 14727 ± 
6658, respectively. However, no significant differences in PDCD11-Ab levels were observed 
among patients with cCI, aCI, and TIA. Thus, PDCD11-Ab levels may be closely related to 
an ischemic brain lesion. 
 
Association between PDCD11-Ab levels and other clinical parameters in validation 
cohort 
   We then examined correlations between PDCD11-Ab levels and other clinical parameters 
in the validation cohort. A weak association was observed between PDCD11-Ab levels and 
age (r = 0.3082, p < 0.0001). PDCD11-Ab levels were higher in females than in males (p = 
0.0073); moreover, the association was higher in patients with cardiovascular disease (CVD) 
than those without the disease (p = 0.0011). A strong association was observed between 
PDCD11-Ab levels and hypertension (p < 0.0001), diabetes (p = 0.0003), and stroke (p < 
0.0001) (Figure 3). No significant correlations were observed between PDCD11-Ab levels 
and other parameters, including hyperlipidemia, obesity, and smoking. 
 
Association between TIA and clinical parameters including PDCD11-Ab levels 
   The cut-off value of PDCD11-Ab for predicting of TIA was determined to be 13921 by 
ROC curve analysis with a sensitivity of 73.6% and a specificity of 55.8%. The area under 
the curve was 0.679. We used HDs and patients with TIA in the validation cohort to 
determine the cut-off value, which was validated in the validation cohort. Of 92 patients with 
TIA and 285 HDs, 66 patients with TIA and 126 HDs tested positive (p < 0.0001 was 
calculated using the chi-square test). 
   Results of univariate and multivariate logistic regression analyses are shown in Table 3. 
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Using the cutoff value of 13921, univariate logistic regression analysis revealed that the 
elevated PDCD11-Ab level was associated with the increased risk of TIA (OR: 3.52, 95% CI: 
2.09–5.93, p < 0.0001). Factors with a univariate p value of less than 0.05 were included in 
the multivariate analysis. Multivariate logistic regression analysis revealed that the elevated 
PDCD11-Ab level was an independent predictor of TIA (OR: 2.44, 95% CI: 1.33–4.57, p = 
0.0039). Predictive value of PDCD11-Ab for TIA was not inferior to other known risk factors 
of TIA including age (OR: 4.97, 95% CI: 2.67–9.48, p < 0.0001); hypertension (OR: 3.21, 
95% CI: 1.76–5.86, p = 0.0001); and diabetes (OR: 4.31, 95% CI: 1.74–11.2, p = 0.0015). 
 
Association of PDCD11-Ab levels with AMI and DM 
   We further examined correlations between PDCD11-Ab levels and AMI and DM in the 
other validation cohort using sera of each 128 age-matched patients and HDs. AlphaLISA 
revealed no significant differences in PDCD11-Ab levels between patients with AMI and DM 
and HDs (Figure 4).  
 
Expression of PDCD11 in human ischemic brain 
   Because PDCD11-Ab levels were elevated specifically in sera from patients with 
ischemic stroke, we further examined PDCD11 protein expression in surgically-resected 
ischemic brain tissue using immunohistochemistry. HE staining showed both viable and 
hollowing cells by necrosis co-existed in the ischemic penumbra (Figure 5A). 
Immunostaining with anti-PDCD11 demonstrated marked expression of PDCD11 in necrotic 
cells but not in normal cells (Figure 5B). 
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DISCUSSION 
 
   The major finding of this study is that PDCD11-Ab levels were elevated in patients with 
symptomatic stroke, which turned out to be an independent predictor of TIA. In accordance 
with our knowledge, this is the first study that has identified autoantibodies against PDCD11, 
which were elevated in sera of TIA patients. 
 
Proposed mechanisms of elevation in PDCD11-Ab levels in patients with TIA and stroke 
   PDCD11 is a NF-B-binding protein that colocalizes with U3 RNA in the nucleolus and 
is required for rRNA maturation and generation of 18S rRNA. PDCD11 is necessary for Fas 
ligand (FasL) expression, and PDCD11 overexpression is known to induce transcription of 
FasL (TNFSF6; 134638), leading to the induction of apoptosis through Fas/FasL/caspase 
death pathway [28–31]. It is also reported that post-stroke inflammatory response of FasL is 
an important contributing mechanism in ischemic brain lesion [32]. Therefore, it can be 
speculated that Fas/FasL/caspase death pathway may be activated in the ischemic brain tissue 
and that PDCD11 may be overexpressed. As the overexpression of cancer related antigens 
stimulate the immunity and produce their autoantibodies, overexpression of PDCD11 in 
ischemic brain tissue might also stimulate autoimmune response and produce the PDCD11 
autoantibody in patients with ischemic stroke. We further examined PDCD11 protein 
expression in surgically-resected ischemic brain tissue using immunohistochemistry to prove 
our speculation. PDCD11 expression was closely co-localized with ischemic brain cells 
(Figure 5). 
   We have screened autoantibody levels in the sera of patients with ischemic stroke and 
report TUBB2C [19], ATP2B4, BMP-1 [20], DHPS [33], and SH3BP5 [34] as possible 
antigens that may be implicated in the development of stroke. Antibody levels against these 
proteins were also elevated in the sera of patients with CVD and DM. Accordingly, we 
speculated that because ischemic stroke is only one of the phenotypes of whole body 
atherosclerosis, stroke associated autoantibodies we have detected may have also been 
elevated in the sera of patients with other atherosclerotic diseases. On the other hand, serum 
PDCD11-Ab levels were elevated only in patients with TIA and stroke but not in those with 
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AMI and DM. This intriguing finding led us to hypothesize that the immune response against 
PDCD11 is not due to the leakage of PDCD11 from atherosclerotic plaques but due to the 
leakage from brain tissues exposed to ischemia. Leakage of the overexpressed PDCD11 from 
ischemic brain tissues may have induced autoimmune responses against PDCD11. 
Immunological research would further verify the mechanisms of PDCD11-Ab elevation in 
the sera of patients with TIA and stroke. 
 
Clinical implications of measuring PDCD11-Ab levels in TIA patients 
   Results of this study suggest that the measurement of serum PDCD11-Ab levels can 
provide valuable information for diagnosing TIA. According to a nationwide survey of 
patients with stroke, approximately 15% of patients with ischemic stroke experiences TIA 
before the onset of stroke [35]. Early medical intervention to TIA is known to prevent the 
development of subsequent stroke; therefore, early and accurate diagnosis of TIA is clinically 
significant. However, approximately half of patients with TIA visited medical facilities after 
their symptoms completely disappeared [36, 37], and the diagnosis of TIA is sometimes 
difficult because physicians have to diagnose TIA only by taking history into consideration. 
Clinical examinations such as MRI, echography of cardia and carotid artery, and Holter 
electrocardiogram may increase the diagnostic accuracy of TIA; however, these are 
expensive, time consuming, and inconvenient. Therefore, if we are able to diagnose TIA 
simply by blood examination, this will significantly contribute to the clinical practice in 
terms of preventing stroke development as well as facilitating medical economy. 
   Although the PDCD11-Ab was significantly elevated in sera of TIA patients independent 
of other cardiovascular risk factors, the diagnostic value of PDCD11 alone was weak 
(sensitivity and specificity were 73.6% and 55.8%, respectively). In our opinion, the 
diagnostic value will improve by a combination of the measurement of the PDCD11-Ab and 
clinical risk factors, including age, hypertension, and diabetes, which were independent 
predictive factors for TIA in the multivariate logistic regression analysis (Table 3). In fact, the 
positive predictive values with the combination of PDCD11-Ab and clinical risk factors were 
higher than those with clinical risk factors alone (Table 4). In addition, we are now trying to 
produce the peptide antigen with a localized epitope, which may improve the sensitivity and 
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specificity. 
   On the other hand, the multivariate logistic regression analysis revealed that the elevation 
of PDCD11-Ab levels was a predictive marker for TIA. Thus, we planned to examine 
PDCD11-Ab by a blood test during the regular medical check-up. If HDs without any 
symptoms have a high level of PDCD11-Ab on this test, they could have high risks for TIA 
or stroke. Hence, examinations should be conducted more carefully. 
 
Conclusion 
 
   In this study, serum PDCD11-Ab levels were found elevated in patients with TIA when 
compared with HDs; thus, it can serve as a biomarker for TIA. Moreover, patients with 
elevated PDCD11-Ab levels may require a more careful and intensive treatment. 
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Table 1. Baseline characteristics of subjects 
 1st  2nd Screening Validation 
 
TIA  
(n = 20) 
aCI  
(n = 96) 
HD 
(n = 96) 
Stroke (n = 621) 
HD  
(n = 285) 
 
 
cCI  
(n = 65) 
aCI  
(n = 464) 
TIA  
(n = 92) 
Age 
(years) 
67.5 
±19.1 
67.7** 
±12.7 
56.3 
±7.1 
73.3** 
±9.2 
75.5** 
±11.5 
70.2** 
±11.6 
52.3 
±11.7 
Male gender 12 
(60.0%) 
73*  
(76.0%)
 
53  
(55.2%) 
48  
(73.8%) 
271  
(58.4%) 
55  
(59.7%) 
188  
(65.9%) 
Hypertension 13 
(65.0%) 
61**  
(63.5%) 
21  
(21.9%) 
53**  
(81.5%) 
335**  
(72.2%) 
60** 
(65.2%) 
57  
(20.0%) 
Diabetes 7  
(35.0%) 
30**  
(31.3%) 
5  
(5.2%) 
22**  
(33.8%) 
125**  
(26.9%) 
26**  
(28.3%) 
11  
(3.9%) 
Hyperlipidem
ia 
8  
(40.0%) 
40**  
(41.7%) 
10  
(10.4%) 
25**  
(38.5%) 
122**  
(26.3%) 
36**  
(39.1%) 
40  
(14.0%) 
CVD 1  
(5.0%) 
7  
(7.3%) 
3  
(3.1%) 
2**  
(3.1%) 
40**  
(8.6%) 
5**  
(5.4%) 
0  
(0.0%) 
Obesity 
(BMI ≥ 25) 
5  
(25.0%) 
24**  
(25.0%) 
31  
(32.3%) 
11  
(16.9%) 
127  
(27.4%) 
30  
(32.6%) 
88  
(30.9%) 
Smoking 11 
(55.0%) 
68**  
(70.8%) 
21  
(21.9%) 
33  
(50.8%) 
228  
(49.1%) 
43  
(46.7%) 
132  
(46.3%) 
Data represents means (±SD) for continuous data and n (%) for categorical data. 
*p<0.01 versus HD, **p<0.001 versus HD.  
TIA, transient ischemic attack; aCI, acute cerebral infarction; HD, healthy donor; cCI, chronic 
cerebral infarction; CVD, cardiovascular disease. 
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Table 2. Genes of candidate antigen in 2nd screening    
Gene 
name 
Full name (Homology) Accession No. CDS 
Site of 
cloned 
region 
PDCD11 programmed cell death 11 (PDCD11) NM_014976.1 88..5703 4833..5581 
CTNNA1 
catenin alpha 1 (CTNNA1), transcript 
variant 1  
NM_001903 128..2848 1808..3801 
ACTR3B 
ARP3 actin-related protein 3 homolog B 
(yeast) (ACTR3B), transcript variant 1  
NM_020445 135..1391 413..1084 
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Table 3. Logistic regression of predictive factors for TIA (n = 377; no. of events = 92) 
 Univariate analysis  Multivariate analysis 
 OR 95%CI p value  OR 95%CI p value 
Age (≥ 60) 9.83 5.67–17.8 <0.0001  4.97 2.67–9.48 <0.0001 
Male 0.73 0.45–1.18 0.2034     
HT 7.38 4.39–12.4 <0.0001  3.21 1.76–5.86 0.0001 
DM 9.96 4.68–21.2 <0.0001  4.31 1.74–11.2 0.0015 
HL 4.01 2.34–6.86 <0.0001  1.93 0.99–3.72 0.0509 
CVD 8.23 1.57–43.2 0.0127  1.33 0.22–10.8 0.7610 
Obesity (BMI ≥ 25) 1.09 0.66–1.82 0.7283     
Smoking 0.99 0.61–1.58 0.9569     
PDCD11 (> 13921)* 3.52 2.09–5.93 <0.0001  2.44 1.33–4.57 0.0039 
*PDCD11, elevated PDCD11-Ab levels. PDCD11-Ab cutoff was 13921 based on ROC curve 
analysis.  
HT, hypertension; DM, diabetes mellitus; HL, hyperlipidemia; CVD, cardiovascular disease; OR, 
odds ratio. 
  
24 
 
Table 4. Validation of predictive factors for TIA (n = 377; no. of events = 92) 
 
Clinical risk factor 
 Clinical risk factor  
+ PDCD11 (> 13921)* 
 TIA(+) TIA(-) PPV  TIA(+) TIA(-) PPV 
Age (≥ 60) 72 79 47.7%  55 40 57.9% 
HT 59 57 50.9%  49 30 62.0% 
DM 26 11 70.3%  22 3 88.0% 
Age (≥ 60) + HT 52 28 65.0%  43 15 74.1% 
Age (≥ 60) + DM 24 5 82.8%  21 1 95.5% 
HT + DM 20 5 80.0%  18 1 94.7% 
Age (≥ 60) + HT + DM 20 2 90.9%  18 0 100% 
*PDCD11, elevated PDCD11-Ab levels. PDCD11-Ab cutoff was 13921 based on ROC curve 
analysis.  
HT, hypertension; DM, diabetes mellitus; PPV, positive predictive value. 
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Figure 1. First screening by SEREX and Western blot analysis. Recombinant proteins were 
blotted onto nitrocellulose membranes and reacted with patient serum. Arrows indicate positive phage 
clones. Positive clones were re-cloned for 2 additional times to obtain monoclonality (A). GST 
protein (lane 1) and affinity-purified GST-tagged PDCD11 (lane 2) were separated on 11% 
SDS-polyacrylamide gels and stained with Coomassie Blue (B), or western blotted using anti-GST 
antibody (C) or the autologous sera of patients with aCI (D), TIA (E), and HD (F). Asterisks indicate 
partially degraded proteins. Molecular weights are shown in the left. 
26 
 
 
 
Figure 2. Serum antibody levels against SEREX antigens examined by AlphaLISA. Antibody 
levels against 3 antigen candidates, PDCD11 (A), CTNNA1 (B), and ACTR3B (C), were compared 
between HDs and patients with aCI in second screening cohort. Alpha counts represent relative 
antibody levels. ***p < 0.0001 and p = 0.2033 were calculated by Mann–Whitney U test. (D) The 
levels of PDCD11-Abs examined by AlphaLISA in the validation cohort. The PDCD11-Ab levels 
were compared between HDs and patients with TIA, aCI, or cCI. ***p < 0.001 was calculated by 
Mann–Whitney U test with type I error adjustment using Bonferroni procedure and not significant 
(n.s.), p = 1 was calculated by Kruskal–Wallis test with type I error adjustment using Bonferroni 
procedure. 
HD, healthy donors; P, patients with acute cerebral infarction; TIA, transient ischemic attack; aCI, 
acute cerebral infarction; cCI, chronic cerebral infarction; Ab, antibody. 
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Figure 3. Association between PDCD11-Ab levels and other clinical parameters in stroke 
patients. Correlations between PDCD11-Ab levels and age (A), gender (B), hypertension (C), 
diabetes (D), hyperlipidemia (E), CVD (F), obesity (BMI ≥ 25) (G), smoking habit (H), and ischemic 
stroke (I). Spearman’s correlation analysis (A) and Mann–Whitney U test (B-I) were used. **p < 0.01, 
***p < 0.001. 
PDCD11-Ab, PDCD11 antibodies; CVD, cardiovascular disease. 
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Figure 4. Association between PDCD11-Ab levels and other atherosclerotic diseases including 
AMI and DM. The mean age ± SDs of HDs and patients with AMI or DM were 58.29 ± 5.63, 58.28 
± 8.5, and 58.37 ± 9.11, respectively. The serum samples of patients with AMI were obtained from 
Kyoto University Hospital, and those of patients with DM were obtained from Chiba University 
Hospital. Kruskal–Wallis test was used to calculate p values. 
AMI, acute myocardial infarction; DM, diabetes mellitus; HD, healthy donors. 
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Figure 5. Immunohistochemistry 
Surgically-resected ischemic brain tissue was stained with hematoxylin only (A), anti-PDCD11 
antibody (B, arrow). 
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